- Home
- DMAC vs JMSB Comparison
DMAC vs JMSB Comparison
Compare DMAC & JMSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- JMSB
- Stock Information
- Founded
- DMAC 2000
- JMSB 2005
- Country
- DMAC United States
- JMSB United States
- Employees
- DMAC N/A
- JMSB N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- JMSB Major Banks
- Sector
- DMAC Health Care
- JMSB Finance
- Exchange
- DMAC Nasdaq
- JMSB Nasdaq
- Market Cap
- DMAC 310.1M
- JMSB 270.0M
- IPO Year
- DMAC N/A
- JMSB N/A
- Fundamental
- Price
- DMAC $6.87
- JMSB $19.82
- Analyst Decision
- DMAC Strong Buy
- JMSB Buy
- Analyst Count
- DMAC 3
- JMSB 2
- Target Price
- DMAC $12.33
- JMSB $22.50
- AVG Volume (30 Days)
- DMAC 448.5K
- JMSB 13.7K
- Earning Date
- DMAC 11-12-2025
- JMSB 10-22-2025
- Dividend Yield
- DMAC N/A
- JMSB 1.50%
- EPS Growth
- DMAC N/A
- JMSB 688.28
- EPS
- DMAC N/A
- JMSB 1.32
- Revenue
- DMAC N/A
- JMSB $56,750,000.00
- Revenue This Year
- DMAC N/A
- JMSB $18.36
- Revenue Next Year
- DMAC N/A
- JMSB $12.36
- P/E Ratio
- DMAC N/A
- JMSB $15.20
- Revenue Growth
- DMAC N/A
- JMSB 59.00
- 52 Week Low
- DMAC $3.19
- JMSB $13.81
- 52 Week High
- DMAC $7.49
- JMSB $26.52
- Technical
- Relative Strength Index (RSI)
- DMAC 63.84
- JMSB 50.05
- Support Level
- DMAC $6.83
- JMSB $20.08
- Resistance Level
- DMAC $7.41
- JMSB $20.85
- Average True Range (ATR)
- DMAC 0.43
- JMSB 0.49
- MACD
- DMAC 0.03
- JMSB -0.04
- Stochastic Oscillator
- DMAC 73.62
- JMSB 37.95
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.